Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Wet Macular Degeneration | 27 | 2022 | 145 | 10.070 |
Why?
|
Macular Degeneration | 39 | 2024 | 980 | 7.000 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 35 | 2024 | 664 | 6.860 |
Why?
|
Macular Edema | 35 | 2022 | 359 | 6.760 |
Why?
|
Recombinant Fusion Proteins | 39 | 2024 | 3772 | 6.010 |
Why?
|
Visual Acuity | 91 | 2023 | 2530 | 6.000 |
Why?
|
Angiogenesis Inhibitors | 55 | 2024 | 2038 | 5.910 |
Why?
|
Choroidal Neovascularization | 26 | 2023 | 343 | 5.220 |
Why?
|
Geographic Atrophy | 11 | 2023 | 66 | 4.190 |
Why?
|
Intravitreal Injections | 49 | 2023 | 344 | 3.840 |
Why?
|
Diabetic Retinopathy | 19 | 2022 | 1210 | 3.510 |
Why?
|
Retinal Vasculitis | 5 | 2023 | 42 | 3.320 |
Why?
|
Vitreous Body | 17 | 2020 | 389 | 2.550 |
Why?
|
Macula Lutea | 6 | 2019 | 151 | 2.470 |
Why?
|
Retinal Vein Occlusion | 14 | 2019 | 137 | 2.320 |
Why?
|
Fluorescein Angiography | 35 | 2023 | 940 | 2.220 |
Why?
|
Tomography, Optical Coherence | 41 | 2022 | 2657 | 2.090 |
Why?
|
Vascular Endothelial Growth Factor A | 35 | 2023 | 3508 | 2.070 |
Why?
|
Vitrectomy | 13 | 2017 | 365 | 1.990 |
Why?
|
Laser Coagulation | 14 | 2019 | 326 | 1.950 |
Why?
|
Eye Diseases | 6 | 2020 | 669 | 1.830 |
Why?
|
Subretinal Fluid | 5 | 2022 | 24 | 1.770 |
Why?
|
Lasers, Solid-State | 3 | 2020 | 169 | 1.660 |
Why?
|
Endophthalmitis | 5 | 2020 | 262 | 1.310 |
Why?
|
Retinal Detachment | 7 | 2016 | 411 | 1.230 |
Why?
|
Vision Disorders | 8 | 2020 | 1058 | 1.190 |
Why?
|
Fundus Oculi | 15 | 2021 | 473 | 1.170 |
Why?
|
Retinal Diseases | 6 | 2023 | 683 | 1.170 |
Why?
|
Retinal Hemorrhage | 2 | 2018 | 96 | 1.110 |
Why?
|
Double-Blind Method | 39 | 2023 | 12026 | 1.090 |
Why?
|
Retina | 17 | 2022 | 2616 | 1.070 |
Why?
|
Ophthalmic Solutions | 6 | 2022 | 317 | 1.010 |
Why?
|
Cataract Extraction | 7 | 2018 | 481 | 0.980 |
Why?
|
Laser Therapy | 4 | 2020 | 1072 | 0.950 |
Why?
|
Myopia, Degenerative | 2 | 2015 | 15 | 0.920 |
Why?
|
Hawks | 1 | 2022 | 1 | 0.870 |
Why?
|
Angioid Streaks | 2 | 2013 | 12 | 0.850 |
Why?
|
Angiopoietin-2 | 1 | 2022 | 173 | 0.760 |
Why?
|
Angiopoietins | 1 | 2021 | 80 | 0.750 |
Why?
|
Retinal Artery Occlusion | 1 | 2020 | 74 | 0.730 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 164 | 0.700 |
Why?
|
Medical Futility | 1 | 2020 | 127 | 0.670 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 188 | 0.650 |
Why?
|
Integrins | 1 | 2022 | 846 | 0.620 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2020 | 482 | 0.620 |
Why?
|
Antibodies, Monoclonal | 14 | 2022 | 9274 | 0.620 |
Why?
|
Vitreoretinopathy, Proliferative | 2 | 2016 | 68 | 0.620 |
Why?
|
Retinal Vessels | 2 | 2021 | 772 | 0.610 |
Why?
|
Parvovirinae | 1 | 2017 | 9 | 0.610 |
Why?
|
Diabetes Mellitus | 5 | 2022 | 5751 | 0.600 |
Why?
|
Treatment Outcome | 55 | 2024 | 63114 | 0.590 |
Why?
|
Endoscopes | 2 | 2014 | 175 | 0.570 |
Why?
|
Ocular Hypotension | 1 | 2016 | 22 | 0.560 |
Why?
|
Aged | 79 | 2023 | 163280 | 0.560 |
Why?
|
Central Serous Chorioretinopathy | 1 | 2016 | 27 | 0.550 |
Why?
|
Sickness Impact Profile | 8 | 2020 | 302 | 0.540 |
Why?
|
Albinism, Oculocutaneous | 1 | 2015 | 17 | 0.520 |
Why?
|
Retreatment | 9 | 2013 | 610 | 0.520 |
Why?
|
Venous Pressure | 1 | 2015 | 56 | 0.520 |
Why?
|
Basement Membrane | 1 | 2016 | 356 | 0.520 |
Why?
|
Eye Infections | 1 | 2015 | 64 | 0.520 |
Why?
|
Photochemotherapy | 5 | 2015 | 807 | 0.520 |
Why?
|
Vancomycin | 1 | 2018 | 501 | 0.510 |
Why?
|
Lenses, Intraocular | 2 | 2015 | 140 | 0.510 |
Why?
|
Hypopigmentation | 1 | 2015 | 41 | 0.510 |
Why?
|
Valsalva Maneuver | 1 | 2015 | 92 | 0.500 |
Why?
|
Iris Diseases | 1 | 2015 | 40 | 0.500 |
Why?
|
Humans | 140 | 2024 | 744343 | 0.500 |
Why?
|
Aged, 80 and over | 46 | 2023 | 57776 | 0.500 |
Why?
|
Fovea Centralis | 3 | 2012 | 119 | 0.500 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2016 | 337 | 0.500 |
Why?
|
Retinal Perforations | 4 | 2018 | 131 | 0.490 |
Why?
|
Pigment Epithelium of Eye | 1 | 2015 | 220 | 0.490 |
Why?
|
Drug Substitution | 2 | 2016 | 281 | 0.490 |
Why?
|
Retinal Neovascularization | 1 | 2017 | 244 | 0.490 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2013 | 12 | 0.470 |
Why?
|
Vitelliform Macular Dystrophy | 1 | 2013 | 12 | 0.470 |
Why?
|
Follow-Up Studies | 29 | 2021 | 39050 | 0.470 |
Why?
|
Emphysema | 1 | 2016 | 247 | 0.460 |
Why?
|
Male | 90 | 2023 | 350118 | 0.450 |
Why?
|
Vitreous Detachment | 3 | 2018 | 22 | 0.430 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2013 | 772 | 0.420 |
Why?
|
Endotamponade | 4 | 2016 | 35 | 0.420 |
Why?
|
Cryosurgery | 2 | 2016 | 453 | 0.420 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2009 | 2282 | 0.410 |
Why?
|
Early Diagnosis | 1 | 2017 | 1184 | 0.410 |
Why?
|
Female | 88 | 2023 | 380194 | 0.400 |
Why?
|
Benzimidazoles | 1 | 2016 | 850 | 0.390 |
Why?
|
Visual Field Tests | 7 | 2022 | 383 | 0.380 |
Why?
|
Porphyrins | 3 | 2009 | 348 | 0.380 |
Why?
|
Endoscopy | 3 | 2016 | 1785 | 0.370 |
Why?
|
Histoplasmosis | 1 | 2010 | 66 | 0.360 |
Why?
|
Bromobenzenes | 1 | 2009 | 2 | 0.360 |
Why?
|
Benzeneacetamides | 1 | 2009 | 39 | 0.350 |
Why?
|
Phenylacetates | 1 | 2009 | 114 | 0.350 |
Why?
|
Benzophenones | 1 | 2009 | 57 | 0.350 |
Why?
|
Middle Aged | 58 | 2023 | 213383 | 0.350 |
Why?
|
Intraocular Pressure | 9 | 2020 | 1270 | 0.350 |
Why?
|
Ketorolac | 1 | 2009 | 79 | 0.340 |
Why?
|
Disease Management | 1 | 2020 | 2459 | 0.340 |
Why?
|
Uveitis, Anterior | 2 | 2000 | 101 | 0.340 |
Why?
|
Photosensitizing Agents | 3 | 2009 | 602 | 0.320 |
Why?
|
Ketorolac Tromethamine | 3 | 2008 | 21 | 0.320 |
Why?
|
Cost Savings | 1 | 2013 | 926 | 0.310 |
Why?
|
Phacoemulsification | 3 | 2010 | 149 | 0.300 |
Why?
|
Exercise Test | 1 | 2015 | 2074 | 0.300 |
Why?
|
Glucocorticoids | 5 | 2014 | 2107 | 0.290 |
Why?
|
Cataract | 2 | 2012 | 834 | 0.290 |
Why?
|
Dinoprostone | 1 | 2009 | 600 | 0.290 |
Why?
|
Prospective Studies | 29 | 2023 | 53288 | 0.280 |
Why?
|
Silicone Oils | 2 | 2016 | 22 | 0.280 |
Why?
|
Fibrinolysin | 2 | 2018 | 131 | 0.280 |
Why?
|
Vitreoretinal Surgery | 2 | 2016 | 27 | 0.260 |
Why?
|
Prednisolone | 2 | 2008 | 334 | 0.250 |
Why?
|
Scleral Buckling | 2 | 2016 | 84 | 0.240 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2020 | 10943 | 0.240 |
Why?
|
Anti-Bacterial Agents | 2 | 2018 | 7181 | 0.230 |
Why?
|
Retinal Pigment Epithelium | 2 | 2021 | 302 | 0.220 |
Why?
|
Dexamethasone | 3 | 2011 | 1951 | 0.220 |
Why?
|
Sulfur Hexafluoride | 2 | 2013 | 25 | 0.220 |
Why?
|
Miosis | 2 | 2015 | 7 | 0.220 |
Why?
|
Color Vision | 1 | 2022 | 21 | 0.210 |
Why?
|
Plasma Kallikrein | 1 | 2021 | 20 | 0.210 |
Why?
|
Monitoring, Ambulatory | 2 | 2016 | 355 | 0.200 |
Why?
|
Drug Implants | 3 | 2011 | 244 | 0.200 |
Why?
|
Injections | 10 | 2010 | 840 | 0.200 |
Why?
|
Glaucoma | 1 | 2011 | 1159 | 0.200 |
Why?
|
Peptides, Cyclic | 1 | 2023 | 400 | 0.190 |
Why?
|
Pseudophakia | 1 | 2000 | 62 | 0.190 |
Why?
|
Visual Fields | 4 | 2016 | 1047 | 0.190 |
Why?
|
Drug Administration Schedule | 3 | 2022 | 4933 | 0.180 |
Why?
|
Hyperthermia, Induced | 1 | 2004 | 403 | 0.180 |
Why?
|
Injections, Intraocular | 1 | 2019 | 30 | 0.180 |
Why?
|
Adult | 23 | 2024 | 214055 | 0.170 |
Why?
|
Tolmetin | 1 | 1999 | 23 | 0.170 |
Why?
|
Tromethamine | 1 | 1999 | 31 | 0.170 |
Why?
|
Drug Combinations | 2 | 2016 | 1959 | 0.170 |
Why?
|
Complement Inactivating Agents | 1 | 2019 | 50 | 0.170 |
Why?
|
Retinal Vein | 1 | 2019 | 47 | 0.170 |
Why?
|
Eye Pain | 2 | 2016 | 47 | 0.160 |
Why?
|
Time Factors | 8 | 2020 | 40075 | 0.160 |
Why?
|
Choroid | 1 | 2020 | 322 | 0.160 |
Why?
|
Postoperative Complications | 3 | 2018 | 15295 | 0.160 |
Why?
|
Prostaglandins F, Synthetic | 1 | 1998 | 32 | 0.160 |
Why?
|
Phenyl Ethers | 1 | 2018 | 58 | 0.160 |
Why?
|
Retrospective Studies | 18 | 2020 | 77449 | 0.160 |
Why?
|
Propanolamines | 1 | 2018 | 167 | 0.150 |
Why?
|
Drug Therapy, Combination | 4 | 2019 | 6489 | 0.150 |
Why?
|
Complement C3 | 1 | 2019 | 461 | 0.150 |
Why?
|
Fluorocarbons | 2 | 2013 | 452 | 0.150 |
Why?
|
Inflammation | 2 | 2023 | 10638 | 0.150 |
Why?
|
Neurofibroma, Plexiform | 1 | 2017 | 71 | 0.140 |
Why?
|
Exudates and Transudates | 2 | 2014 | 172 | 0.140 |
Why?
|
Air | 1 | 2016 | 182 | 0.140 |
Why?
|
Isoindoles | 1 | 2015 | 41 | 0.130 |
Why?
|
Administration, Topical | 3 | 2009 | 690 | 0.130 |
Why?
|
Administration, Oral | 2 | 2020 | 3913 | 0.130 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2014 | 26 | 0.130 |
Why?
|
Immunocompetence | 1 | 1995 | 137 | 0.130 |
Why?
|
Drug Compounding | 1 | 2016 | 242 | 0.120 |
Why?
|
Sulfonic Acids | 1 | 2014 | 96 | 0.120 |
Why?
|
Magnetic Resonance Angiography | 1 | 2021 | 1442 | 0.120 |
Why?
|
Exophthalmos | 1 | 1995 | 97 | 0.120 |
Why?
|
Receptor, TIE-2 | 1 | 2014 | 178 | 0.120 |
Why?
|
Eye Infections, Fungal | 1 | 1995 | 110 | 0.120 |
Why?
|
Europe | 1 | 2020 | 3339 | 0.120 |
Why?
|
Carotid Stenosis | 1 | 2021 | 854 | 0.120 |
Why?
|
Peptide Fragments | 2 | 2018 | 5097 | 0.110 |
Why?
|
Incidence | 6 | 2020 | 20947 | 0.110 |
Why?
|
Surgical Wound Dehiscence | 1 | 1994 | 215 | 0.110 |
Why?
|
Ankyrin Repeat | 1 | 2012 | 17 | 0.110 |
Why?
|
Hospitals, Military | 1 | 1993 | 67 | 0.110 |
Why?
|
Telemedicine | 3 | 2016 | 2872 | 0.110 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13695 | 0.110 |
Why?
|
Chronic Disease | 3 | 2016 | 9146 | 0.110 |
Why?
|
Prognosis | 5 | 2020 | 29063 | 0.110 |
Why?
|
Biological Availability | 2 | 2012 | 397 | 0.110 |
Why?
|
Dependovirus | 1 | 2017 | 706 | 0.100 |
Why?
|
Mycoses | 1 | 1995 | 376 | 0.100 |
Why?
|
Indocyanine Green | 1 | 2013 | 239 | 0.100 |
Why?
|
Neurofibromatosis 1 | 1 | 2017 | 569 | 0.100 |
Why?
|
Eye Injuries, Penetrating | 1 | 1993 | 115 | 0.100 |
Why?
|
Ciliary Neurotrophic Factor | 1 | 2011 | 77 | 0.100 |
Why?
|
Anesthesia, Local | 1 | 2013 | 275 | 0.100 |
Why?
|
Coloring Agents | 1 | 2013 | 566 | 0.100 |
Why?
|
Eye Injuries | 2 | 2010 | 245 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2000 | 1790 | 0.090 |
Why?
|
Disease Progression | 5 | 2020 | 13284 | 0.090 |
Why?
|
Ophthalmoscopy | 1 | 2011 | 176 | 0.090 |
Why?
|
Blast Injuries | 2 | 2010 | 302 | 0.090 |
Why?
|
Lens Implantation, Intraocular | 3 | 2008 | 192 | 0.090 |
Why?
|
Ligaments | 1 | 2010 | 128 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2618 | 0.090 |
Why?
|
Aniline Compounds | 1 | 2014 | 986 | 0.090 |
Why?
|
Integrin alpha5beta1 | 1 | 2009 | 38 | 0.090 |
Why?
|
Tamoxifen | 1 | 1994 | 981 | 0.090 |
Why?
|
Suture Techniques | 1 | 1994 | 798 | 0.090 |
Why?
|
Lenses | 2 | 2008 | 45 | 0.090 |
Why?
|
Emergency Medical Technicians | 1 | 2010 | 116 | 0.090 |
Why?
|
Exfoliation Syndrome | 1 | 2010 | 110 | 0.090 |
Why?
|
Eye Proteins | 1 | 2013 | 646 | 0.090 |
Why?
|
Propionates | 1 | 2009 | 169 | 0.080 |
Why?
|
Drug Delivery Systems | 1 | 2000 | 2219 | 0.080 |
Why?
|
Equipment Design | 2 | 2014 | 3582 | 0.080 |
Why?
|
Drug Costs | 1 | 2016 | 1105 | 0.080 |
Why?
|
Diabetes Mellitus, Type 1 | 5 | 2015 | 3336 | 0.080 |
Why?
|
Single-Blind Method | 2 | 2013 | 1590 | 0.080 |
Why?
|
Costs and Cost Analysis | 1 | 2013 | 1681 | 0.080 |
Why?
|
Pyrrolidines | 1 | 2009 | 342 | 0.080 |
Why?
|
Genetic Vectors | 1 | 2017 | 3420 | 0.070 |
Why?
|
Neoplasms | 1 | 2016 | 21683 | 0.070 |
Why?
|
Drug Resistance | 1 | 2013 | 1609 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2022 | 13989 | 0.070 |
Why?
|
Genetic Markers | 1 | 2013 | 2634 | 0.070 |
Why?
|
Peptides | 2 | 2022 | 4409 | 0.070 |
Why?
|
Sinusitis | 1 | 1995 | 923 | 0.070 |
Why?
|
Microsurgery | 1 | 2011 | 796 | 0.070 |
Why?
|
Eye Infections, Bacterial | 1 | 2008 | 235 | 0.070 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2009 | 1572 | 0.070 |
Why?
|
Health Education | 1 | 2012 | 1056 | 0.060 |
Why?
|
Tissue Distribution | 1 | 2009 | 2327 | 0.060 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 12959 | 0.060 |
Why?
|
Piperazines | 1 | 2015 | 2488 | 0.060 |
Why?
|
United States | 5 | 2020 | 69872 | 0.060 |
Why?
|
DEAE-Dextran | 1 | 2024 | 10 | 0.060 |
Why?
|
Atrophy | 1 | 2009 | 1583 | 0.060 |
Why?
|
Streptococcal Infections | 1 | 2008 | 638 | 0.060 |
Why?
|
Optics and Photonics | 1 | 2005 | 321 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2009 | 1770 | 0.060 |
Why?
|
Fibrinolytic Agents | 1 | 2013 | 2158 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2014 | 3798 | 0.060 |
Why?
|
Prosthesis Implantation | 1 | 2008 | 642 | 0.060 |
Why?
|
Pyrimidines | 1 | 2015 | 2942 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5391 | 0.060 |
Why?
|
Miniaturization | 3 | 2008 | 164 | 0.050 |
Why?
|
Calcaneus | 1 | 2004 | 138 | 0.050 |
Why?
|
Fibrosis | 1 | 2009 | 2029 | 0.050 |
Why?
|
Mass Spectrometry | 1 | 2009 | 2203 | 0.050 |
Why?
|
Lipoma | 1 | 2004 | 334 | 0.050 |
Why?
|
Orbit | 2 | 1995 | 426 | 0.050 |
Why?
|
Ophthalmic Artery | 1 | 2021 | 60 | 0.050 |
Why?
|
Neurofibromin 2 | 1 | 2022 | 267 | 0.050 |
Why?
|
Emergency Medicine | 1 | 2010 | 1207 | 0.050 |
Why?
|
Cross-Over Studies | 1 | 2006 | 2029 | 0.050 |
Why?
|
Reoperation | 3 | 2016 | 4201 | 0.050 |
Why?
|
Health Care Costs | 1 | 2013 | 3209 | 0.040 |
Why?
|
Staphylococcal Infections | 1 | 2008 | 1400 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.040 |
Why?
|
Blood-Retinal Barrier | 1 | 2019 | 62 | 0.040 |
Why?
|
Carotid Artery, Internal | 1 | 2021 | 445 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2015 | 11725 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7279 | 0.040 |
Why?
|
Anterior Chamber | 1 | 1999 | 197 | 0.040 |
Why?
|
Genotype | 1 | 2013 | 12951 | 0.040 |
Why?
|
Research Design | 1 | 2014 | 5987 | 0.040 |
Why?
|
Pyridines | 1 | 2009 | 2825 | 0.040 |
Why?
|
Signal Transduction | 1 | 2021 | 23403 | 0.040 |
Why?
|
Blood Flow Velocity | 1 | 2021 | 1423 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2016 | 20129 | 0.040 |
Why?
|
Carotid Arteries | 1 | 2021 | 952 | 0.040 |
Why?
|
Candida albicans | 1 | 2000 | 394 | 0.040 |
Why?
|
False Positive Reactions | 2 | 2012 | 981 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2011 | 3923 | 0.030 |
Why?
|
Quality of Life | 5 | 2023 | 12804 | 0.030 |
Why?
|
Acute Disease | 2 | 2011 | 7149 | 0.030 |
Why?
|
Middle East | 2 | 1993 | 219 | 0.030 |
Why?
|
Capillaries | 1 | 2019 | 773 | 0.030 |
Why?
|
Mitosporic Fungi | 1 | 1995 | 20 | 0.030 |
Why?
|
Phenotype | 1 | 2013 | 16365 | 0.030 |
Why?
|
Endothelium, Corneal | 2 | 2008 | 199 | 0.030 |
Why?
|
Aspergillus | 1 | 1995 | 85 | 0.030 |
Why?
|
Capillary Permeability | 1 | 2019 | 798 | 0.030 |
Why?
|
Iatrogenic Disease | 1 | 1998 | 547 | 0.030 |
Why?
|
Serotonin Receptor Agonists | 1 | 2015 | 152 | 0.030 |
Why?
|
Safety | 1 | 1999 | 1186 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2012 | 15076 | 0.030 |
Why?
|
Cell Count | 2 | 2008 | 1856 | 0.030 |
Why?
|
Crystallization | 1 | 1994 | 524 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2014 | 666 | 0.030 |
Why?
|
Complement Factor H | 1 | 2013 | 110 | 0.030 |
Why?
|
Paranasal Sinuses | 1 | 1995 | 250 | 0.030 |
Why?
|
Aqueous Humor | 1 | 2012 | 161 | 0.030 |
Why?
|
Tissue Adhesions | 1 | 2013 | 235 | 0.030 |
Why?
|
Nasal Mucosa | 1 | 1995 | 373 | 0.030 |
Why?
|
Sclerostomy | 1 | 2011 | 15 | 0.030 |
Why?
|
Office Visits | 1 | 2016 | 598 | 0.030 |
Why?
|
Light | 1 | 1998 | 1374 | 0.030 |
Why?
|
Glaucoma, Open-Angle | 1 | 1998 | 706 | 0.020 |
Why?
|
Animals | 2 | 2022 | 168757 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2004 | 2529 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 7913 | 0.020 |
Why?
|
Case Management | 1 | 2013 | 286 | 0.020 |
Why?
|
Apolipoproteins | 1 | 2013 | 317 | 0.020 |
Why?
|
Capsules | 1 | 2011 | 196 | 0.020 |
Why?
|
Radiation Injuries | 1 | 1998 | 1180 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2009 | 18029 | 0.020 |
Why?
|
Cadaver | 1 | 1994 | 1337 | 0.020 |
Why?
|
Antifungal Agents | 1 | 1995 | 730 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2012 | 892 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2000 | 6171 | 0.020 |
Why?
|
Complement System Proteins | 1 | 2013 | 795 | 0.020 |
Why?
|
Explosions | 1 | 2010 | 109 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5078 | 0.020 |
Why?
|
Streptococcus mitis | 1 | 2008 | 8 | 0.020 |
Why?
|
Epiretinal Membrane | 1 | 2009 | 68 | 0.020 |
Why?
|
Viridans Streptococci | 1 | 2008 | 15 | 0.020 |
Why?
|
Pain, Postoperative | 1 | 1999 | 1643 | 0.020 |
Why?
|
Sensory Aids | 1 | 2008 | 44 | 0.020 |
Why?
|
Staphylococcus epidermidis | 1 | 2008 | 117 | 0.020 |
Why?
|
Sensitivity and Specificity | 3 | 2012 | 14722 | 0.020 |
Why?
|
Absorbable Implants | 1 | 2010 | 342 | 0.020 |
Why?
|
Risk Factors | 5 | 2014 | 72290 | 0.020 |
Why?
|
Vision, Ocular | 1 | 2011 | 464 | 0.020 |
Why?
|
Premedication | 1 | 2008 | 258 | 0.020 |
Why?
|
Terrorism | 1 | 2010 | 211 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2010 | 601 | 0.020 |
Why?
|
Contrast Sensitivity | 1 | 2008 | 244 | 0.020 |
Why?
|
Emergencies | 1 | 1993 | 1170 | 0.020 |
Why?
|
Ultrasonography | 1 | 2000 | 5985 | 0.020 |
Why?
|
Fibronectins | 1 | 2009 | 726 | 0.020 |
Why?
|
Pilot Projects | 2 | 2011 | 8324 | 0.020 |
Why?
|
Equipment Safety | 1 | 2006 | 264 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3870 | 0.020 |
Why?
|
Registries | 1 | 2020 | 8089 | 0.020 |
Why?
|
Military Personnel | 1 | 1993 | 1133 | 0.020 |
Why?
|
Wound Healing | 1 | 1994 | 2785 | 0.010 |
Why?
|
Intraoperative Complications | 1 | 2010 | 1198 | 0.010 |
Why?
|
Rabbits | 1 | 2009 | 4894 | 0.010 |
Why?
|
Equipment Failure Analysis | 1 | 2005 | 868 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 25625 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2009 | 3144 | 0.010 |
Why?
|
Optic Disk | 1 | 2006 | 400 | 0.010 |
Why?
|
Photography | 1 | 2005 | 520 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 19905 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8642 | 0.010 |
Why?
|
Protein Binding | 1 | 2012 | 9386 | 0.010 |
Why?
|
Physical Therapy Modalities | 1 | 2004 | 550 | 0.010 |
Why?
|
Blood Pressure | 1 | 2014 | 8554 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2009 | 5974 | 0.010 |
Why?
|
Prosthesis Design | 1 | 2005 | 2110 | 0.010 |
Why?
|
Proteins | 1 | 2013 | 6103 | 0.010 |
Why?
|
Cell Movement | 1 | 2009 | 5217 | 0.010 |
Why?
|
Prevalence | 1 | 1994 | 15226 | 0.010 |
Why?
|
Anterior Eye Segment | 1 | 1998 | 152 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2006 | 2418 | 0.010 |
Why?
|
Postoperative Care | 1 | 2004 | 1486 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2009 | 11366 | 0.010 |
Why?
|
Cell Line | 1 | 2009 | 15997 | 0.010 |
Why?
|
Aging | 1 | 2014 | 8664 | 0.010 |
Why?
|
Recurrence | 1 | 2006 | 8340 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 10481 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15519 | 0.010 |
Why?
|
Hospitalization | 1 | 1993 | 10262 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2006 | 15540 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 1994 | 20822 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2004 | 35421 | 0.000 |
Why?
|
Infant | 1 | 1993 | 35136 | 0.000 |
Why?
|
Child, Preschool | 1 | 1993 | 41006 | 0.000 |
Why?
|
Child | 1 | 1993 | 77709 | 0.000 |
Why?
|
Adolescent | 1 | 1993 | 85781 | 0.000 |
Why?
|